Drug Profile
Research programme: brain disease therapeutics - Lundbeck/Janssen
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Janssen; Lundbeck A/S
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Depressive disorders
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Alzheimer's-disease in Europe
- 28 Jan 2019 No recent reports of development identified for research development in Depressive disorders in Europe
- 22 Dec 2014 Early research in Alzheimer's disease in Europe (unspecified route)